Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Sutro Biopharma's Enterprise Value is €276.88 Mil.
Sutro Biopharma's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was €-95.71 Mil. Therefore, Sutro Biopharma's EV-to-EBIT ratio for today is -2.89.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Sutro Biopharma's Enterprise Value is €276.88 Mil.
Sutro Biopharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was €-89.96 Mil. Therefore, Sutro Biopharma's EV-to-EBITDA ratio for today is -3.08.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Sutro Biopharma's Enterprise Value is €276.88 Mil.
Sutro Biopharma's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was €86.03 Mil. Therefore, Sutro Biopharma's EV-to-Revenue ratio for today is 3.22.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Sutro Biopharma's Enterprise Value is €276.88 Mil.
Sutro Biopharma's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €-130.90 Mil. Therefore, Sutro Biopharma's EV-to-FCF ratio for today is -2.12.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Sutro Biopharma (FRA:S090) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Sutro Biopharma's current Enterprise Value is €276.88 Mil.
Sutro Biopharma's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-95.71 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Sutro Biopharma's current Enterprise Value is €276.88 Mil.
Sutro Biopharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-89.96 Mil.
Sutro Biopharma's current Enterprise Value is €276.88 Mil.
Sutro Biopharma's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €86.03 Mil.
Sutro Biopharma's current Enterprise Value is €276.88 Mil.
Sutro Biopharma's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-130.44 Mil.
Sutro Biopharma's current Enterprise Value is €276.88 Mil.
Sutro Biopharma's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-130.90 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sutro Biopharma Enterprise Value Related Terms
Sutro Biopharma Enterprise Value Historical Data
* Premium members only.
The historical data trend for Sutro Biopharma's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:S090 vs NGNE, OCGN, CBIO: Enterprise Value Comparison
For the Biotechnology subindustry, Sutro Biopharma's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sutro Biopharma Enterprise Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sutro Biopharma's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Sutro Biopharma's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Sutro Biopharma's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sutro Biopharma (FRA:S090) has a Enterprise Value of €276.88 Mil as of Jul. 04, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Sutro Biopharma and its competitors.
Is Sutro Biopharma's Enterprise Value too high?
Sutro Biopharma's current Enterprise Value is €276.88 Mil. Overall, Sutro Biopharma has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sutro Biopharma's Enterprise Value compare to NGNE and OCGN?
Sutro Biopharma's Enterprise Value of €276.88 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Biotechnology company?
A good Enterprise Value depends on the Biotechnology industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Sutro Biopharma and its competitors. Sutro Biopharma's current Enterprise Value is €276.88 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sutro Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Sutro Biopharma (FRA:S090) is currently considered Significantly Overvalued. The stock's GF Value™ is €10.30, compared to a current price of €25.20 — trading 144.7% above its estimated fair value. The current Enterprise Value is €276.88 Mil. Sutro Biopharma's overall GF Score™ is 41/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Sutro Biopharma (FRA:S090), the current Enterprise Value is €276.88 Mil as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sutro Biopharma (FRA:S090) Overvalued in 2026?
Based on GuruFocus' analysis, Sutro Biopharma stock appears to be overvalued.
The current stock price of €25.20 is trading 144.7% above its estimated GF Value™ of €10.30.
GuruFocus considers Sutro Biopharma to be Significantly Overvalued.
Key valuation signals for FRA:S090:
Enterprise Value: €276.88 Mil
GF Value™: €10.30 vs. price of €25.20 (144.7% above fair value)
No single metric tells the full story. See the FRA:S090 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
41GF Score
Get the complete analysis for FRA:S090
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:S090 has been successfully added to your 
